* MaxCyte Inc is expected to show a fall in quarterly revenue when it reports results on November 6 for the period ending September 30 2024

* The Rockville Maryland-based company is expected to report a 7.9% decrease in revenue to $7.374 million from $8 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for MaxCyte Inc is for a loss of 12 cents per share.

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for MaxCyte Inc is $9.50​, above​ its last closing price of $3.77. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.13 -0.13 -0.09 Beat 28.9

Mar. 31 2024 -0.13 -0.13 -0.09 Beat 30.8

Dec. 31 2023 -0.07 -0.07 -0.05 Beat 30.6​

Sep. 30 2023 -0.10 -0.10 -0.11 Missed -7.8

​​Jan. -0.10 -0.10 -0.10 Met -4.2

1 0001

Mar. 31 2023 -0.11 -0.11 -0.11 Met 1.8​

Dec. 31 2022 -0.07 -0.05 Beat 28.6

Sep. 30 2022 -0.09 -0.08 -0.06 Beat 26.8

This summary was machine generated November 4 at 21:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)